Filing Flows › Bicycle Therapeutics (BCYC) › Q2 2026 › vs Q2 2025
Bicycle Therapeutics (BCYC) Q2 2026 vs Q2 2025 (year over year)
Bicycle Therapeutics's revenue fell $2.3M (-78%) from $2.9M in Q2 2025 to $629K in Q2 2026.
Bicycle Therapeutics, Q2 2026: revenue $629K (-78% year over year), net loss $50.3M, operating cash flow −$49.6M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $629K | $2.9M | −$2.3M | -78% |
| Other income, net | $4.3M | $7.4M | −$3.1M | -42% |
| Net loss | $50.3M | $79.0M | −$28.6M | -36% |
| Costs & expenses | $55.3M | $89.5M | −$34.2M | -38% |
| Operating costs | $55.2M | $89.5M | −$34.3M | -38% |
| Income tax | $90K | −$231K | $321K | — |
| Research & development | $41.2M | $71.0M | −$29.9M | -42% |
| General & admin | $14.0M | $18.5M | −$4.5M | -24% |
| Operating cash sources | $57.1M | $83.9M | −$26.8M | -32% |
| Depreciation & amortization | $1.1M | $1.7M | −$629K | -37% |
| Share-based compensation | $6.4M | $9.4M | −$3.0M | -32% |
| Cash used in operations | $49.6M | $72.8M | −$23.2M | -32% |
| Net loss absorbed | $50.3M | $79.0M | −$28.6M | -36% |
| Working capital & other | $6.7M | $5.0M | $1.8M | +36% |
Questions
How much did Bicycle Therapeutics's revenue grow year over year in Q2 2026?
Bicycle Therapeutics's revenue fell $2.3M (-78%) from $2.9M in Q2 2025 to $629K in Q2 2026.